The Alzheimer Cohorts Consortium is supported by an unrestricted grant from the Janssen Prevention Center to the Harvard T.H. Chan School of Public Health. Age, Gene/Environment Susceptibility (AGES) This study is supported by National Institute of Aging contracts (N01-AG-12100 and HHSN271201200022C) with contributions from the National Eye Institute, National Institute on Deafness and Other Communication Disorders, and the National Heart, Lung and Blood Institute, the National Institute of Aging Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament); Atherosclerosis Risk in Communities (ARIC) This study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). Neurocognitive data is collected by (U01 HL096812, HL096814, HL096899, HL096902, HL096917) with funding also provided by the National Institute of Neurologic Disorders and Stroke; Cardiovascular Health Study (CHS) This research was supported by contracts (HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086), and grants U01HL080295, U01HL130114 and HL105756 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by the National Institute on Aging (R01AG023629) and, in part, by grants (AG20098, AG15928, and AG05133). The funding sources did not have any role in the study design; collection, analysis, or interpretation of data; preparation of the manuscript; or decision to submit it for publication; Cognitive Function and Ageing Studies (CFAS) Medical Research Council (MRC) CFAS I was funded by the MRC (Research Grant: G9901400) and the National Health Service (NHS). CFAS II has been supported by the UK Medical Research Council (Research Grant:G06010220) and received additional support from the National Institute for Health Research (NIHR), comprehensive clinical research networks in West Anglia, Nottingham City and Nottinghamshire County NHS Primary Care trusts and the dementias and neurodegenerative disease research Network (DeNDRoN) in Newcastle; Framingham Heart Study (FHS) This work was supported by the National Heart, Lung, and Blood Institute’s Framingham Heart Study (contracts N01-HC-25195 and HHSN268201500001I). This study was also supported by grants from the National Institute on Aging: (AG054076, U01-AG049505, and AG008122 (S. Seshadri)). S. Seshadri and A. Beiser were also supported by additional grants from the National Institute on Aging (R01AG049607, AG033193, AG033040) and the National Institute of Neurological Disorders and Stroke (R01-NS017950); The Gothenburg study This study was supported by grants from The Swedish Research Council 2012-5041, 2015-02830, 2013-8717, Swedish Research Council for Health, Working Life and Wellfare (no 2001-2646, 2003-0234, 2004-0150, 2006-0020, 2008-1229, 2012-1138, 2004-0145, 2006-0596, 2008-1111, 2010-0870, 2013-1202, 2001-2849, 2005-0762,2008-1210, 2013-2300, 013-2496, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Hja¨rnfonden, Sahlgrenska University Hospital (ALF), The Alzheimer’s Association Zenith Award (ZEN-01-3151), The Alzheimer’s Association Stephanie B. Overstreet Scholars (IIRG-00-2159), Alzheimer’s Association (IIRG-03-6168), The Alzheimer’s Association (IIRG-09-131338), Eivind och ElsaK:son Sylvans stiftelse, Stiftelsen So¨derstro¨m-Ko¨nigska Sjukhemmet, Stiftelsen fo¨ r Gamla Tja¨narinnor, Handlanden Hjalmar Svenssons Forskningsfond, Stiftelsen Professor Bror Gadelius’ Minnesfond, Swedish Alzheimer foundation; PAQUID The PAQUID cohort was supported by IPSEN France, NOVARTIS Pharma France, and the CNSA (Caisse Nationale de Solidarité et d’Autonomie). This study is supported by the Erasmus Medical Centre and Erasmus University Rotterdam, The Netherlands Organization for Scientific Research (NWO), The Netherlands Organization for Health Research and Development (ZonMW), the Research Institute for Diseases in the Elderly (RIDE), The Netherlands Genomics Initiative, the Ministry of Education, Culture and Science, the Ministry of Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. Further support was obtained from the Netherlands Consortium for Healthy Ageing and the Dutch Heart Foundation (2012T008). This research was further supported by funding from the European Union Seventh Framework Program (FP7/2007e2013) under grant agreement no. 601055, VPHDare@ IT (FP7-ICT-2011-9e601055); and funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 667375 (Co-STREAM) and under grant agreement no. 678543 (European Research Council (ERC) funded project: ORACLE). None of the funding organizations or sponsors were involved in study design, in collection, analysis, and interpretation of data, in writing of the report, or in the decision to submit the article for publication; The 3-Cites Study This study is conducted under a partnership agreement among the Institut National de la Santé et de la Recherche Médicale (INSERM), the Victor Segalen–Bordeaux II University, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, Mutuelle Générale de l’Education Nationale (MGEN), Institut de la Longévité, Conseils Régionaux of Aquitaine and Bourgogne, Fondation de France, and Ministry of Research–INSERM Programme ‘‘Cohortes et collections de donne´es biologiques’’; Infrastructure for the CHARGE Consortium is supported in part by National Heart, Lung and Blood Institute (HL105756) and for the neurology working group by National Institutes of Aging (AG033193 and AG049505).